Engle E K, Fisher D A C, Miller C A, McLellan M D, Fulton R S, Moore D M, Wilson R K, Ley T J, Oh S T
Division of Hematology, Washington University School of Medicine, St Louis, MO, USA.
The Genome Institute, Washington University School of Medicine, St Louis, MO, USA.
Leukemia. 2015 Apr;29(4):869-76. doi: 10.1038/leu.2014.289. Epub 2014 Sep 25.
Clonal architecture in myeloproliferative neoplasms (MPNs) is poorly understood. Here we report genomic analyses of a patient with primary myelofibrosis (PMF) transformed to secondary acute myeloid leukemia (sAML). Whole genome sequencing (WGS) was performed on PMF and sAML diagnosis samples, with skin included as a germline surrogate. Deep sequencing validation was performed on the WGS samples and an additional sample obtained during sAML remission/relapsed PMF. Clustering analysis of 649 validated somatic single-nucleotide variants revealed four distinct clonal groups, each including putative driver mutations. The first group (including JAK2 and U2AF1), representing the founding clone, included mutations with high frequency at all three disease stages. The second clonal group (including MYB) was present only in PMF, suggesting the presence of a clone that was dispensable for transformation. The third group (including ASXL1) contained mutations with low frequency in PMF and high frequency in subsequent samples, indicating evolution of the dominant clone with disease progression. The fourth clonal group (including IDH1 and RUNX1) was acquired at sAML transformation and was predominantly absent at sAML remission/relapsed PMF. Taken together, these findings illustrate the complex clonal dynamics associated with disease evolution in MPNs and sAML.
骨髓增殖性肿瘤(MPNs)中的克隆结构目前仍知之甚少。在此,我们报告了一例原发性骨髓纤维化(PMF)转化为继发性急性髓系白血病(sAML)患者的基因组分析结果。对PMF和sAML诊断样本进行了全基因组测序(WGS),并将皮肤作为种系替代样本纳入分析。对WGS样本以及在sAML缓解期/复发的PMF期间获取的另一个样本进行了深度测序验证。对649个经过验证的体细胞单核苷酸变异进行聚类分析,发现了四个不同的克隆组,每个克隆组都包含推定的驱动突变。第一组(包括JAK2和U2AF1)代表起始克隆,在所有三个疾病阶段都有高频突变。第二克隆组(包括MYB)仅存在于PMF中,表明存在一个对转化可有可无的克隆。第三组(包括ASXL1)在PMF中低频出现,在后续样本中高频出现,表明优势克隆随疾病进展而演变。第四克隆组(包括IDH1和RUNX1)在sAML转化时获得,在sAML缓解期/复发的PMF中基本不存在。综上所述,这些发现阐明了与MPNs和sAML疾病演变相关的复杂克隆动态。